Cargando…

EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells

BACKGROUND: Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. In traditional anti-cancer therapy, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) have been proven to be beneficial f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Hao, Li, Yongwen, Yuan, Yin, Li, Weiting, Zhang, Hongbing, Zhang, Zihe, Shi, Ruifeng, Liu, Minghui, Liu, Chao, Chen, Chen, Liu, Hongyu, Chen, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716470/ https://www.ncbi.nlm.nih.gov/pubmed/33276757 http://dx.doi.org/10.1186/s12885-020-07667-7

Ejemplares similares

HOTAIR promotes gefitinib resistance through modification of EZH2 and silencing p16 and p21 in non-small cell lung cancer
por: Li, Weiting, et al.
Publicado: (2021)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

miR-182 suppresses invadopodia formation and metastasis in non-small cell lung cancer by targeting cortactin gene
por: Li, Yongwen, et al.
Publicado: (2018)

EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation
por: Li, Ying, et al.
Publicado: (2021)

Identification of small proline‐rich protein 1B (SPRR1B) as a prognostically predictive biomarker for lung adenocarcinoma by integrative bioinformatic analysis
por: Zhang, Zihe, et al.
Publicado: (2021)

Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy
por: Cao, Peijun, et al.
Publicado: (2023)

ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer
por: Zhu, Guangsheng, et al.
Publicado: (2021)

Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Lung Adenocarcinoma
por: Huang, Hua, et al.
Publicado: (2022)

Pyroptosis-Related LncRNA Signatures Correlate With Lung Adenocarcinoma Prognosis
por: Huang, Hua, et al.
Publicado: (2022)

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors
por: Liu, Minghui, et al.
Publicado: (2016)

Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
por: Li, Xin, et al.
Publicado: (2020)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
por: Li, Amin, et al.
Publicado: (2020)

Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer
por: Regzedmaa, Orgilmaa, et al.
Publicado: (2019)

TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription
por: Yuan, Weiwei, et al.
Publicado: (2019)

HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib
por: Jin, Qian, et al.
Publicado: (2021)

Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
por: Yang, Hua, et al.
Publicado: (2016)

Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells
por: Chen, Yun-Ju, et al.
Publicado: (2011)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance
por: Liu, Minghui, et al.
Publicado: (2021)

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib
por: He, Peng, et al.
Publicado: (2013)

HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer
por: Liu, Minghui, et al.
Publicado: (2018)

Construction of a circular RNA–microRNA–messenger RNA regulatory network of hsa_circ_0043256 in lung cancer by integrated analysis
por: Li, Yongwen, et al.
Publicado: (2021)

Overactivation of histone deacetylases and EZH2 in Wilms tumorigenesis
por: Chen, Chao-Hui, et al.
Publicado: (2022)

The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
por: Xin, Shuang, et al.
Publicado: (2015)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

Docosahexaenoic Acid Serving As Sensitizing Agents And Gefitinib Resistance Revertants In EGFR Targeting Treatment
por: Ding, Xuansheng, et al.
Publicado: (2019)

Germline EGFR mutations in lung cancer (Review)
por: Liu, Minghui, et al.
Publicado: (2023)

Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration
por: Wang, Mingyao, et al.
Publicado: (2022)

Secretagogin, a marker for neuroendocrine cells, is more sensitive and specific in large cell neuroendocrine carcinoma compared with the markers CD56, CgA, Syn and Napsin A
por: Dong, Yunlong, et al.
Publicado: (2020)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
por: Alfieri, Roberta R, et al.
Publicado: (2011)

Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study
por: Hou, Xue, et al.
Publicado: (2023)

Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors
por: Gibaja, V, et al.
Publicado: (2016)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib
por: WANG, XINZHAO, et al.
Publicado: (2015)

The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro
por: Khalil, Ashraf, et al.
Publicado: (2017)

Efficacy and safety of EGFR inhibitor gefitinib in recurrent or metastatic cervical cancer: a preliminary report
por: Krishna, Abhishek, et al.
Publicado: (2023)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p61j9m1pfd8i93hfmefgme0rv9